Shionogi & Co has entered into a license agreement with Hsiri Therapeutics regarding a collaborative licensing, research and development program to discover and develop novel therapeutics for non-tuberculous mycobacterial (NTM) diseases and tuberculosis (TB). The candidate compounds discovered by Hsiri have a novel mechanism of action and are hence anticipated to be more effective than…